All In Biotech

Investigational drug · Phase 2

INT-210

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ulcerative Colitis (UC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "INT-210"

First trial start

2026

Jun 11, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "INT-210", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Ulcerative Colitis (UC)

Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "INT-210" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Ulcerative Colitis (UC)

  • Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials

    Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)

  • MORF-057zotemtegrast, LY4268989Phase 24 trials

    Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)

  • Biocad · Ulcerative Colitis (UC), Crohn's Disease (CD)

  • HSK47388Phase 22 trials

    Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)

  • MB-001Phase 21 trial

    Mage Biologics · Ulcerative Colitis (UC)

  • MGT-006Phase 21 trial

    Metagen Therapeutics, Inc. · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate

  • MT-201Phase 21 trial

    Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease

  • MT-501Phase 21 trial

    Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.